Stockreport

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF - Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p - Acoramidis mitigated the rise in NT-proBNP through Month 54 t [Read more]